Mutant mice lacking the cholecystokinin2 receptor show a dopamine-dependent hyperactivity and a behavioral sensitization to morphine

Neuroscience Letters

Volumn 306, Issue 1-2, 2001, Pages 41-44

  Daugé, Valérie ^a   Beslot, Françoise ^a   Matsui, Toshimitsu ^b   Roques, Bernard Pierre ^a  

^a Laboratoire de Pharmacochimie   (France)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amphetamine; Cholecystokinin2 receptor deficient mice; Cocaine; Dopamine antagonists; Morphine; Sensitization

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; CHOLECYSTOKININ RECEPTOR; COCAINE; DOPAMINE; MORPHINE; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SENSITIZATION;

EID: 0035933669     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(01)01867-5     Document Type: Article

References (16)

1. Anxiolytic effects of CCK-B antagonists
2. Biological actions of cholecystokinin
3. The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats
4. Effect of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine
5. CCK in anxiety and cognitive processes
6. Evidence for coexistence of dopamine and CCK in mesolimbic neurones
7. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area
8. Dopamine transmission in the initiation and expression of drug and stress-induced sensitization of motor activity
9. The CCK-B agonist, BC264 increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats
10. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo
11. CCK-B receptor: Chemistry, molecular biology, biochemistry and pharmacology
12. RPR 102681 increases limbic dopamine release, shows antidepressant activity and reduces the rewarding properties of psychostimulants
13. 8. Functional significance of subregional distribution
14. Cholecystokinin (CCK) and schizophrenia: The selective CCK-B antagonist LY262691 decreases midbrain dopamine unit activity
15. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: Multiple substrates for opiate-dopamine interactions
16. Cholecystokinin and psychiatric disorders